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The Efficacy and Safety of Photoselective Vaporization of the 
Prostate with a Potassium-titanyl-phosphate Laser for 
Symptomatic Benign Prostatic Hyperplasia according to Prostate 
Size: 2-Year Surgical Outcomes
Hyung Suk Kim, Min Chul Cho, Ja Hyeon Ku, Soo Woong Kim, Jae-Seung Paick
Department of Urology, Seoul National University College of Medicine, Seoul, Korea
Purpose: We investigated 2-year follow-up outcomes of patients who underwent potas-
sium-titanyl-phosphate (KTP)-photoselective vaporization of the prostate (PVP) laser 
therapy for symptomatic benign prostatic hyperplasia (BPH).
Materials and Methods: Of a total of 169 patients who underwent 80 W KTP-PVP by 
a single surgeon, we retrospectively analyzed the clinical data of 74 patients who com-
pleted 2 years of follow-up. The efficacy of the PVP was assessed at 1, 3, 6, 12, and 24 
months postoperatively by use of the International Prostate Symptom Score (IPSS) and 
uroflowmetry with postvoid residual urine volume (PVR). Safety, including complica-
tions, was evaluated at each visit.    
Results: Mean preoperative total prostate and transitional zone volumes were 42.3 ml 
(range, 34.0-59.0 ml) and 18.6 ml (range, 10.1-28.6 ml) respectively. According to both 
IPSS and uroflowmetry, compared with baseline, the improvement in each parameter 
was sustained significantly at both 1 and 2 years postoperatively (p＜0.05). There were 
no serious intraoperative complications, such as massive hemorrhage requiring trans-
fusion or transurethral resection syndrome. Transient gross hematuria occurred in 16 
(21.6%) cases, urgency incontinence in 6 (8.1%) cases, bladder neck contracture (BNC) 
in 3 (4.1%) cases, and urethral stricture in 1 (2.7%) case. The cases of urethral stricture 
and BNC developed only in the group with a prostate size of less than 45 ml. No cases 
required reoperation due to re-growing prostatic tissue.
Conclusions: PVP seems to be a safe and effective procedure for the surgical treatment 
of symptomatic BPH. After PVP, the subjective and objective improvements in the mic-
turition parameters were sustainable up to 2 years, with minimal complications.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the most com-
mon illnesses occurring in post-middle-aged men, and its 
importance and frequency are increasing at a dramatic 
pace [1]. The initial treatment of BPH is mostly through 
medication, but some patients who show no improvements 
in their conditions with medication choose surgical treat-
ment [2]. Furthermore, when BPH is coupled with re-
current urinary retention, urinary tract infection (UTI), 
bladder stone, renal insufficiency, or gross hematuria, sur-
gical treatment is considered first over medical manage-
ment [2]. Transurethral resection of the prostate (TURP) 
is the most standard surgical procedure performed for BPH 
to date [3]. However, complications such as bleeding, retro-
grade ejaculation, and transurethral resection syndrome 
(TUR syndrome) can occur after TURP [4]. In order to mini-
mize such complications, minimally invasive procedures, 
such as photoselective vaporization of the prostate (PVP) 
using lasers, have been introduced. Recent PVP procedures 
have used high-energy 80 W potassium-titanyl-phosphate 
(KTP) lasers and 120 W lithium-triborate (LBO) lasers. 
Numerous studies have shown that PVP shows surgical 
outcomes similar to those of TURP, but reduces the hospi-Korean J Urol 2010;51:330-336
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TABLE 1. Baseline patient characteristics and perioperative outcome data
Prostate size Overall (n=74) ＜45 ml (n=39) ≥45 ml (n=35) p-value
Median (interquartile range)
Baseline characteristics
　Age (years) 66.5 (62.0-72.2) 65.0 (62.0-69.5) 67.0 (62.0-74.5) 0.286
　PSA (ng/ml) 1.8 (0.9-3.2) 1.2 (0.7-2.1) 2.6 (1.6-4.0) ＜0.001
　Serum creatinine (mg/dl) 1.1 (1.0-1.2) 1.1 (1.0-1.1) 1.1 (1.0-1.2) 0.514
　Total prostate volume (ml) 42.3 (34.0-59.0) 35.0 (30.0-39.8) 59.2 (51.3-77.0) ＜0.001
　Transition zone volume (ml) 18.6 (10.1-28.6) 11.5 (8.2-18.0) 29.2 (23.3-43.5) ＜0.001
UDS finding
　BOO index 27.0 (19.5-43.2) 24.0 (13.0-43.0) 36.0 (22.0-46.0) 0.045
　Poor compliance (No./total) 3/74 1/39 2/35
　Involuntary detrusor contraction (No./total) 13/74 7/39 6/35
Perioperative outcomes
　Operation time (min) 50.0 (38.0-60.0) 45.0 (29.0-57.0) 53.0 (42.0-75.0) 0.004
　Applied energy (kJ) 132.8 (88.9-172.5) 128.0 (78.5-167.3) 154.2 (101.9-210.5) 0.018
　Catheterization time (days) 1.1 (0.0-3.0) 1.0 (0.0-3.0) 1.2 (1.0-3.0) 0.013
　Hospitalization time (days) 2.2 (1.0-4.0) 2.1 (1.0-4.0) 2.3 (2.0-4.0) 0.008
Statistical comparison between less than 45 ml and more than 45 ml groups using Mann-Whitney U test. PSA: prostate-specific antigen, 
BOO: bladder outlet obstruction
tal stay and catheterization time dramatically and further 
reduces bleeding, thereby decreasing possible complica-
tions [5-7]. To date, short-term results of PVP domestically 
have been presented on a number of occasions, but mid- to 
long-term results are largely lacking. Therefore, the aim 
of this study was to report 2-year surgical outcomes and du-
rability of PVP in the treatment of symptomatic BPH.  
MATERIALS AND METHODS
This study was approved by the Institutional Review Board 
(IRB approval number: H-1003-021-311) at the Seoul 
National University Hospital. Between January 2006 and 
July 2007, 169 men with lower urinary tract symptoms 
(LUTS) or BPH that did not respond to medical treatment 
with an alpha-blocker underwent PVP by a single surgeon. 
Only 74 patients who had 2 years of follow-up data after 
the PVP procedure were included in this retrospective 
study. The exclusion criteria were as follows: 5-alpha-re-
ductase inhibitor use, presence of an indwelling urinary 
catheter, previous prostate surgery, urethral stricture, 
prostate malignancy, and neurogenic bladder disease. All 
patients underwent a preoperative evaluation with trans-
rectal ultrasound (TRUS) and multichannel video urody-
namics (MMS UD-2000, Medical Measurement System, 
Enschede, The Netherlands) in addition to a standard eval-
uation for LUTS and BPH, including history, physical ex-
amination with digital rectal examination, International 
Prostate Symptom Score (IPSS), urinalysis, 3-day fre-
quency-volume chart (FVC), serum creatinine, and serum 
prostate-specific antigen (PSA). After the PVP, the efficacy 
of this treatment for LUTS/BPH was assessed at 1, 3, 6, 12, 
and 24 months postoperatively by use of the IPSS and uro-
flowmetry with post-void residual urine volume (PVR). 
　Safety, including postoperative adverse events, was 
evaluated at each follow-up visit. To assess the subjective 
and objective surgical outcomes, and their durability on the 
basis of prostate size, the patients were stratified into two 
groups according to the median prostate volume: a prostate 
volume less than 45 ml (n=39) versus a prostate volume of 
45 ml or greater (n=35). 
　All variables are reported as medians (25th, 75th percen-
t i l e s )  o r  a s  n u m b e r s  o f  p a t i e n t s  w i t h  p e r c e n t a g e s  i n  
parentheses. The variables were evaluated for statistically 
significant differences between the baseline measures and 
the measures obtained after PVP by use of the Wilcoxon 
signed-rank test. The comparative analysis between the 
two groups was performed by using the Mann-Whitney U 
test for continuous variables and the Fisher’s exact test for 
categorical variables. A 5% level of significance was adopt-
ed for all statistical testing, and all statistical tests were 
two-sided. The Statistical Package for the Social Sciences 
(SPSS for Windows, release 12.0, SPSS Inc., Chicago, IL, 
USA) was used for the data analysis.
RESULTS
The baseline data are shown in Table 1. In all patients, total 
prostate volume and transitional volume were 42.3 ml 
(range, 34.0-59.0 ml) and 18.6 ml (range, 10.1-28.6 ml), 
respectively. The larger size group (total prostate volume 
≥  45 ml) had significantly higher PSA values, bladder out-
let obstruction index, and total energy used than did the 
smaller size group (total prostate volume ＜45 ml) (p＜ 
0.05). Also, the former had a significantly longer operation 
time, duration of catheterization, and hospital stay than 
did the latter (p＜0.05). 
　Table 2 lists the subjective and objective surgical out-Korean J Urol 2010;51:330-336
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TABLE 3. Postoperative complications
Complications
Overall
No. of case (%)
＜45 ml group
No. of case (%)
≥  45 ml group
No. of case (%)
Retrograde ejaculation
Transient hematuria
Dysuria
Urge incontinence
Bladder neck contracture
Urethral stricture
27 (36.5)
16 (21.6)
2 (2.7)
6 (8.1)
3 (4.1)
1 (1.4)
17 (23.0)
10 (13.5)
1 (1.4)
4 (5.4)
3 (4.1)
1 (1.4)
10 (13.5)
6 (8.1)
1 (1.4)
2 (2.7)
0 (0.0)
0 (0.0)
comes and compares the changes in the parameters of the 
IPSS and uroflowmetry with PVR between the smaller size 
and the larger size groups. Overall, total IPSS, subtotal 
voiding symptom score, quality of life (QoL) index, max-
imum flow rate (Qmax), and PVR all showed significant im-
provement compared with baseline starting from 1 month, 
and these improvements were maintained up to 24 months 
postoperatively. The subtotal storage symptom score 
showed significant improvement compared with baseline 
starting from 3 months postoperatively, and this improve-
ment also was maintained up to 24 months post-
operatively. These tendencies were also observed in the 
smaller size group. However, in the larger size group, there 
was no significant improvement compared with baseline 
in the PVR at 24 months postoperatively or in the Qmax 
at 12 and 24 months postoperatively. 
　There was no significant difference in the change from 
baseline for the median values of the subtotal voiding 
symptom scores, Qmax, and PVR at 1, 3, 6, 12, and 24 
months postoperatively between the two groups. However, 
the changes from baseline in the median values of the sub-
total storage symptom scores, total IPSS at 6 months, and 
QoL index at 3, 6, and 12 months postoperatively were sig-
nificantly higher in the larger size group than in the small-
er size group (p＜0.05) (Table 2).
　There were no serious intraoperative complications, 
such as intraoperative bleeding that required transfusion 
or TUR syndrome. Postoperative complications were 16 
cases of hematuria (21.6%), 6 of urinary incontinence 
(8.1%), 1 of urethral stricture (2.7%), and 3 of bladder neck 
contracture (4.1%), with urethral stricture and bladder 
neck contracture occurring only in the smaller size group. 
In 4 cases (5.4%), complications with bladder neck con-
tracture and urethral stricture led to urethral dilatation 
and endoscopic internal urethrotomy, but there was no 
case of re-growth of prostate tissue that led to reoperation 
(Table 3).
DISCUSSION
The KTP laser belongs to the green light spectrum and is 
not easily absorbed by water but is absorbed by the red 
blood cells in tissues with plentiful blood vessels, such as 
in the prostate, resulting in excellent hemostatic and tissue 
removal effects through vaporization [8]. The recent devel-
opment of the 80 W and above KTP and LBO lasers has in-
creased the vaporization speed dramatically and has led to 
an increased use of these lasers. Unlike TURP, PVP results 
in minimal bleeding, making endoscopic viewing possible; 
has little hematuria; and has a reduced time of dependency 
on the Foley catheter; furthermore, PVP is reported to have 
the same treatment effectiveness as TURP [5-7].
　Choo et al, who presented a retrospective review over 2 
years of 104 patients who received 80 W PVP-KTP for BPH, 
reported improvements in parameters such as IPSS, 
Qmax, QoL score, and PVR from 1 month after the PVP that 
were maintained up to 24 months postoperatively, similar 
to the current study [9]. However, the number of patients 
reviewed by Choo et al over the 2 years progressively de-
creased, and they did not report for subtotal scores for the 
IPSS [9].
　The results of the current study showed that total IPSS, 
subtotal voiding symptom scores, QoL index, Qmax, and 
PVR were significantly improved compared with baseline 
starting from 1 month after the PVP, and these improve-
ments were maintained up to 24 months postoperatively. 
Only the subtotal storage symptom scores showed sig-
nificant improvement starting from 3 months post-
operatively, and these improvements were also main-
tained for up to 2 years. These findings agree with existing 
reports that after prostatectomy, improvement in storage 
symptoms occurs later than that in voiding symptoms. 
After PVP, PVR is reduced, thus increasing the time it 
takes for bladder filling; this results in improvements in 
frequency, nocturia, and other such storage symptoms, 
which then leads to the resolution of obstruction [10].
　In the present study, the most common complication was 
retrograde ejaculation, which was observed in 27 cases 
(36.5%). Compared with the rate after TURP, however, the 
frequency of this complication was low [4,11]. Hwang et al 
reported a rate of retrograde ejaculation of 66.9% [12], and 
Lee et al reported a rate of 11% [13]. Malek et al reported 
that less than 26% of patients complained of retrograde 
ejaculation [14], and Te et al reported that it was observed 
in 36% of patients [5]. 
　The exact reason for this difference in the incidence of ret-
rograde ejaculation between TURP and PVP is unknown. 
According to Te et al, however, the reason for the lower in-
cidence of retrograde ejaculation after PVP than after 
TURP may be that vaporization by laser cannot easily re-Korean J Urol 2010;51:330-336
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FIG. 1. Severe pin-point type BNC developed at 1 year after the 
PVP. After one endoscopic ureterotomy, there was no recurrence 
of BNC. BNC: bladder neck contracture, PVP: photoselective 
vaporization of the prostate.
move muscle fiber, thereby conserving the functionality of 
the bladder neck [5]. In the case of the current study, not 
all patients were asked whether retrograde ejaculation de-
veloped; it was only recorded for those patients who com-
plained of such symptoms. Therefore, the actual number 
suffering from retrograde ejaculation could have been 
higher. 
　In our study, there was no serious intraoperative bleed-
ing that required transfusion or caused Foley catheter 
occlusion. As presented by Reich et al, even when PVP was 
performed on 66 patients with a high risk of cardiopulmo-
nary functions who were taking anticoagulant medication 
or with hemorrhage-related illnesses, the PVP was per-
formed safely with minimal bleeding [15]. In cases in which 
bleeding is a major concern, PVP can be a valid alternative 
to TURP for treating BPH patients surgically.
　In relation to high-volume prostates, varying views exist 
on the effectiveness and safety of PVP. Horasanli et al re-
ported that TURP was a preferred treatment over PVP for 
large prostates on the basis of their study comparing the 
results of 76 randomly selected patients whose volume was 
over 70 cc and who underwent PVP or TURP procedures. 
Horasanli et al showed that although the PVP group 
showed a shorter duration of catheterization and hospital 
stay than did the TURP group, the operation time was lon-
ger; improvements in IPSS, Qmax, and PVR were less; and 
7 (17.9%) of those who underwent PVP required reopera-
tion due to re-growing prostatic tissue [16]. Hwang et al al-
so reported negative results of PVP used for large prostates 
in their study of the efficacy and safety of PVP. They showed 
that for prostates above 60 cc, no improvements were seen 
in IPSS or QoL, the duration of catheterization was longer, 
and the incidence of frequent urination and urgency was 
higher [12].
　However, Sandhu et al reported that even for large pros-
tates, PVP is an effective treatment. In their study of 64 pa-
tients with prostate volumes of over 60 cc for 1 year after 
PVP, Qmax increased on average from 7.9 ml/s to 18.9 ml/s, 
PVR dropped from 189 ml to 109 ml, and total IPSS dropped 
from 18.4 to 6.7, with only 1 patient (2%) requiring reopera-
tion [17]. According to Choo et al, when comparisons were 
made between two groups based on a cutoff volume of 60 
cc, there were no significant differences in IPSS, QoL index, 
or Qmax between the smaller and the larger size groups [9]. 
However, PVR was significantly higher in the group with 
prostate volumes higher than 60 cc. At 12 and 24 months 
after PVP, the total IPSS, QoL index, Qmax, and PVR all 
improved in both groups compared with baseline, with to-
tal IPSS, QoL index, and Qmax showing no difference be-
tween the two groups. PVR was significantly higher in the 
larger size group at 12 months after PVP [7]. However, the 
accuracy of this result cannot be verified because of the dif-
ference in the number of patients between the two groups 
(86 vs. 18) [9]. In our study, the cutoff volume was 45 cc, 
which made the number of the two groups similar, and the 
two groups showed no significant differences in any base-
line parameter. In both groups, total IPSS, subtotal voiding 
symptom scores, subtotal storage symptom scores, and 
QoL index showed significant improvements compared 
with baseline that lasted for up to 24 months. For Qmax 
at 12 and 24 months, and for PVR at 24 months after PVP, 
however, there were no improvements in the larger size 
group. This can be interpreted as selection bias due to fol-
low-up loss occurring for those patients whose symptoms 
were alleviated within 1 year after the PVP. That is, only 
those patients whose symptoms had not improved were fol-
lowed up from the original group (n=169). Subtotal voiding 
symptom scores, Qmax, and PVR improvements showed no 
significant differences between the two groups, but greater 
levels of improvement were seen in the larger size group 
for total IPSS and subtotal storage symptom scores at 6 
months after PVP, and for QoL index at 3, 6, and 12 months 
after PVP, respectively. Operation time, applied energy, 
duration of catheterization, and hospital stay were all 
found to be significantly less in the smaller size group. In 
a study by Ruszat et al, in which three prostate volume 
groups were created on the basis of cutoffs of 40 ml and 80 
ml, the group with less volume showed less improvement, 
which was similar to our study [18]. 
　Concerning the postoperative complications that devel-
oped in the present study, there was 1 case of urethral stric-
ture (1.4%) and 3 cases of bladder neck contracture (4.1%), 
with all complications being in the smaller size group. The 
characteristics and photographs of each bladder neck con-
tracture are illustrated in Figs. 1, 2, and 3. The study done 
by Ruszat et al showed that complications such as urethral 
stricture and bladder neck contracture were higher in the 
group with a prostate volume of less than 40 ml. The reason 
presented by those authors for the high number of urethral 
strictures in the small prostate group was that during the 
surgery, moving the laser scope close to the bulbomem-Korean J Urol 2010;51:330-336
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FIG. 3. Mild BNC occurred at 6 months after the PVP. The contrac-
ture was resolved after two urethral soundation. BNC: bladder 
neck contracture, PVP: photoselective vaporization of the prostate.
branous urethra to preserve the sphincter could have led 
to mucosal injury, which then contributed to the stricture. 
To prevent bladder neck contracture during the PVP proce-
dure for small sized prostates, the authors performed pro-
phylactic bladder neck incisions [18]; in our study, how-
ever, these types of procedures were not separately per-
formed. In the current study, for all such complications, en-
doscopic interventions (urethrotomy, urethral dilatation) 
were performed, with the reoperation rate for complica-
tions being 5.6%. Of the complications reported by 
Rassweiler et al after TURP, urethral stricture was 
2.2-9.8% and bladder neck contracture was 0.3-9.2%, with 
the reoperation rate being 3-14.5%, which is similar to the 
current study [19], leading to the conclusion that the in-
cidence of late complications is similar between the PVP 
and TURP procedures.
　The limitations of this study include the following. First, 
the present study was a retrospective review only, which 
could have resulted in selection bias. Second, this study 
was based on a small cohort with a small number of cases 
and we reported only the mid-term results. Third, our study 
was not a randomized controlled study done through com-
FIG. 2. BNC with an impacted urethral stone developed at 3 
months after PVP (A). At 6 months after endoscopic urethrotomy 
and stone removal, a pin-point type BNC recurred (B). At 14 
months after the 2nd endoscopic urethrotomy, multiple penile 
urethral strictures occurred (C). BNC: bladder neck contracture, 
PVP: photoselective vaporization of the prostate.Korean J Urol 2010;51:330-336
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parison with TURP, which is still known as the gold stand-
ard of BPH surgical management. Therefore, we cannot 
completely exclude the placebo effects or bias that may 
have affected the study results. 
　However, domestically, virtually no data exist on the 
long-term effects of PVP, which will allow the current study 
to be a meaningful evaluation tool and database for domes-
tic long-term effectiveness. 
CONCLUSIONS
As a surgical procedure for treating BPH, PVP using the 
KTP laser was found to be a very effective treatment that 
resulted in improvements in objective and subjective mic-
turition parameters that were maintained for a period of 
2 years at the minimum with few complications. PVP with 
the KTP laser can also be an effective and safe procedure 
for patients with larger prostate volumes. However, longer 
follow-up studies with a larger cohort are necessary to con-
firm these findings.
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